Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index-Reference-Cited by-同舟云学术

Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index

Published:2019-04-29 Issue:6 Volume:37 Page:640-650
ISSN:1087-0156
Container-title:Nature Biotechnology
language:en
Short-container-title:Nat Biotechnol

Author:

Shen Wen^ORCID,De Hoyos Cheryl L.,Migawa Michael T.,Vickers Timothy A.,Sun Hong,Low Audrey^ORCID,Bell Thomas A.,Rahdar Meghdad,Mukhopadhyay Swagatam,Hart Christopher E.,Bell Melanie,Riney Stan,Murray Susan F.,Greenlee Sarah,Crooke Rosanne M.,Liang Xue-hai^ORCID,Seth Punit P.,Crooke Stanley T.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Biomedical Engineering,Molecular Medicine,Applied Microbiology and Biotechnology,Bioengineering,Biotechnology

Link

http://www.nature.com/articles/s41587-019-0106-2.pdf

Reference50 articles.

1. Crooke, S. T. Molecular mechanisms of antisense oligonucleotides. Nucleic Acid Ther. 27, 70–77 (2017).

2. Khvorova, A. & Watts, J. K. The chemical evolution of oligonucleotide therapies of clinical utility. Nat. Biotechnol. 35, 238–248 (2017).

3. Swayze, E. E. & Bhat, B. in Antisense Drug Technology—Principles, Strategies, and Applications 2nd edn (ed. Crooke, S. T.) 143–182 (CRC Press, 2008).

4. Frazier, K. S. Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist’s perspective. Toxicol. Pathol. 43, 78–89 (2015).

5. Swayze, E. E. et al. Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res. 35, 687–700 (2007).

Cited by 212 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DNA/RNA heteroduplex technology with cationic oligopeptide reduces class-related adverse effects of nucleic acid drugs;Molecular Therapy - Nucleic Acids;2024-09

2. Advances in structural-guided modifications of siRNA;Bioorganic & Medicinal Chemistry;2024-08

3. Antisense oligonucleotides enhance SLC20A2 expression and suppress brain calcification in a humanized mouse model;Neuron;2024-08

4. A therapeutic approach for the hepatitis C virus: in silico design of an antisense oligonucleotide-based candidate capsid inhibitor;Virus Genes;2024-07-31

5. Current concepts of the crosstalk between lncRNA and E2F1: shedding light on the cancer therapy;Frontiers in Pharmacology;2024-07-25